End-Stage Renal FailureNCT01126905
Mean Reticulated Haemoglobin (Hb) Content (RetHe) Analysis of Renal Patients
An observational study of End-Stage Renal Failure and Functional Iron Deficiency, run by University of Ulster.
Trial summary
Anaemia is a common complication of Chronic Kidney Disease (CKD) the management of which has been aided by the use of synthetic recombinant human erythropoietin therapy (r-HuEPO). Read more about this study
- Who is it for?
- Ages 16 to 85 years
- Conditions the study is for
- End-Stage Renal Failure, Functional Iron Deficiency
- How many people
- 250 participants
- Where
- No sites listed yet
- Study dates
- Jun 2010to 7 Oct 2010
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 to 85 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Renal Patients requested to participate in study (consent required)
Who may be able to join
- Two groups of random routine anonamised blood samples (for use in determinimg a local normal range for the Reticulated Haemoglobin Content [RetHe])will be included in the study:
- Normal red blood cell (RBC) Indices (Hb , Haematocrit, Mean Cell Volume ande Mean Cell Haemoglobin Content) ; an attempt will be made to select an equal mixture of men / women and an appropriate age spread to provide a valid control range for the group of test subjects (renal patients) The student Investigator will ask Haematology staff to record minimum details of iron deficient patients and "normal" test results noted at routine validation [positive identification number (barcode)/ age / sex] - these samples will be coded and additionally analysed for RetHe test.
Who cannot join
- All renal patient who have had surgery and / or a Blood Transfusion OR bleeding episodes within the last month prior to the study are excluded as this would interfere with red cell parameters.
- All patients < 16 years and >85 years are excluded from the study.
About this study
Official title: A Local Pilot Evaluation of Laboratory Monitoring of Renal Patients on Erythropoietin and /or Iron Therapy Using Mean Reticulated Haemoglobin Equivalent (RetHe) and Their Response to Therapy
Anaemia is a common complication of Chronic Kidney Disease (CKD) the management of which has been aided by the use of synthetic recombinant human erythropoietin therapy (r-HuEPO). This red cell stimulating agent creates the further complication of Functional Iron Deficiency (FID) where, despite normal iron stores, patients fail to respond to therapy as they do not possess enough available iron to meet the demand of increased red cell production. Effective response to r-HuEPO therapy depends on an appropriate monitoring of 'available' iron levels.
Previous research into the clinical utility of testing for reticulated haemoglobin concentrations (Ret He) instead of Serum Ferritin and Transferrin Saturation analysis has indicated an advantage as an iron deficient prognostic marker however, further knowledge is required on the use of this new laboratory test (RetHe) to predict Functional Iron Deficiency (FID) level and to study it's relationship with responses to therapy.
Read more
This proposed study aims to estimate a local working Normal (non deficient) and Iron Deficient Reticulated Haemoglobin Content (RET He) reference range from surplus anonamous samples. Routine monthly blood samples from Pre Dialysis and Haemodialysis patients will be used to evaluate the sensitivity and specificity of the RET He test compared to current laboratory tests and investigate its predictive ability for Functional Iron Deficiency in these patients.
Studying , measuring and statistically analysing the change in the RET He parameters in Haemodialysis and Pre Dialysis patients over 3 months will look for evidence of a direct relationship between RET He values and the patients response to therapy. The data will be used to provide a predictive picture of what levels of RET He indicate Functional Iron Deficiency.
The introduction of this test (RetHe) may provide clinicians with a one sample/one test control over iron therapies and ensure the patient gets the most benefit from erythropoietin therapy.
Read the detailed description
Reference Range Testing for new test RET-He will be performed on excess blood available on randomly selected anonamised samples obtained from the daily workload of the laboratory once all the clinically requested analysis has been completed.
100 samples (50 men / 50 women)determined to have normal parameters(as defined by Dacie et al, 10th Edition) and 100 samples (50 men / 50 women)determined to be iron deficient (as defined by Dacie et al, 10th Edition)will be processed for new test parameter (RetHe) under a coded number to ensure no identifying data is recorded. The samples will be archived and and held within the lab for 24 hours prior to routine disposal in accordance with NHS Fife Waste Management Policy.The data will be analysed using a paired t test to determine significant differences and reference range inferred inferred.
Evaluation of sensitivity / specificity of new Ret He test in determinimg iron deficiency and functional iron deficiency and it's response to terapy will be tested using Haemodialysis and Pre-Dialysis Patient Samples (~180 Haemodialysis Patients and ~250 Pre Dialysis Patients)that are obtained during their normal renal unit / clinic appointments.
All consenting NHS Fife Haemodialysis /Pre Dialysis patients will be allocated a 'Subject Identification Number' as part of this study (which will be noted at the top of their Consent Form). This number will be used by the Student Investigator to generate a confidential Coding Key which will be kept separate from data information and secure uner an NHS password protected computer. This will ensure care of personal information and will be used through-out the study by the student investigator to record all generated data.
Patients will be grouped into categories such as Dialysis / Pre Dialysis on a coded SPSS (statistical software) file.
All consenting patients will attend their routine scheduled Renal Clinic appointments as normal (no additional appointments are necessary for this pilot study)and their response to therapy will be observed using the new RetHe test parameter compared to existing laboratory tests utlised (FBC,Ferritin and Transferrin Saturation Levels)
Haemodialysis Patients - June 2010, July 2010*, August 2010
(* NB: In July 2010 Haemodialysis patients are scheduled to have their Ferritin and Transferrin Saturation Levels checked and therfore no additional sample will be required)
- Routine venesection of EDTA (purple topped) sample for Full Blood Count (FBC) Test
- Routine venesection of Clotted (yellow topped) sample for Biochemistry Analysis
- Additional venesection of extra yellow topped sample for non routine Ferritin Test(*usually scheduled every 3 months- routine date due: July 2010)
- Renal Unit Staff label samples and complete request form: Haematology section ticked for: FBC (as normal routine) , Retics (to allow addition of new Ret He test to FBC analysis) and Ferritin (additional request in June and August) Biochemistry section ticked for : All routinely requested Biochemistry tests (such as Urea and Electrolytes) plus additional request for Transferrin Saturation Levels (in June and August)
- Sample and Requests sent to Fife Area Lab for Analysis The project will be carried out within NHS Fife Area Laboratory Haematology Department and will involve the use of NHS premises, facilities and staff.
- Request checked at Laboratory Central Reception (sample and request form labelled with unique positive barcode identification)
- Request Forms sent to central request entry and samples delivered to appropriate laboratories
- FBC samples checked prior to analysis to check request details entered into Laboratory Host Computer System
- FBC sample loaded onto Sysmex XE2100 Haematology Analyser for testing
- Bidirectional Computer Link between Laboratory Host Computer System and Analyser ensures sample tested for FBC and additionally requested RETIC (reticulocyte analysis)
- Sysmex XE2100 automatically analyses sample for Red Blood Cell Indices and additionally uses fluorescent polymethine dye to stain for RNA/DNA content of reticulated cells (early red blood cell precursors). The analyser uses inbuilt Flow Cytometry and measures forward scatter to separate cells by size (this is reported as RBC-Y and RET-Y)
- Sysmex XE2100 RETIC Master software (recently upgraded packaged loaded onto NHS Fife Analysers)uses an algorithm (RET-He = 5.5569e 0.001RET-Y) to convert RET-Y into a reportable mean reticulocyte haemoglobin content (RET He) which is expressed in picograms.
- The sample once analysed is removed from the analyser and the results are either autovalidated and archived (if results are within normal range) or held for validation by a NHS Fife qualified Biomedical Scientist.
- The routinely requested FBC results are available for clinicians within same timescale as normal (no delay due to additional RetHe analysis)
- The sample is archived under their unique identifying barcode numbers and held within the lab for 24 hours prior to routine disposal in accordance with NHS Fife Waste Management Policy.
- The new RetHe value will be held on Sysmex XE2100 analyser (not activated as a reportable test to NHS Fife Biomedical Scientists or clinical staff.)
- The Student Investigator will (on same day as analysis) retrospectively generate a Renal Unit worklist from the Laboratory Host Computer System which will indicate: how many samples received, barcode numbers, names of patients.
- The Student Investigator will (on same day as analysis) retrospectively use the generated worklist to search the Sysmex XE2100 analysers for Ret-He test results and the host computer system for results of Ferritin and Transferrin Saturation Levels.
- The barcode number of the patient and their test results will initially be recorded in the student investigators laboratory handbook (the generated worklist will be discarded into NHS Fife Confidential Waste)
- The student investigator will record the test values into a coded SPSS (statistical software) file for appropriate analysis.
- The investigator will retrospectively match the test data with therapy regime data provided by the Renal Unit (monthly meetings)
Pre Dialysis Patients: June 2010, July 2010, August 2010
(NB: Pre Dialysis Patients are tested 3 monthly so over period of study should get a baseline sample from each consenting patient. Only those patients who are considered iron replete and are placed on 5 week course of iron therpay will be further tested at their follow-up appointments in order to measure response to therapy)
- Routine venesection of EDTA (purple topped) sample for Full Blood Count (FBC) Test, clotted (yellow topped) for Ferritin and clotted (yellow topped)sample for Transferrin Saturation Levels
- Renal Unit Staff label samples and complete request form: Haematology section ticked for: FBC (as normal routine) , Retics (to allow addition of new Ret He test to FBC analysis) and Ferritin (routine request) Biochemistry section ticked for : All routinely requested Biochemistry tests (such as Urea and Electrolytes) plus routine request for Transferrin Saturation Levels
- Sample and Requests sent to Fife Area Lab for Analysis
The project will be carried out within NHS Fife Area Laboratory Haematology Department and will involve the use of NHS premises, facilities and staff (same process as points 6 - 21 above)
- Keywords
- Reticulated Haemoglobin Equivalent, Functional Iron Deficiency, Response to therapy, Iron deficiency
- Medical subject headings
- Kidney Failure, Chronic, Iron Deficiencies
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 May 2010 (estimated)
- Study startJun 2010
- Primary completion7 Oct 2010
- Study completion7 Oct 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for End-Stage Renal FailureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 250 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Ulster
- Sponsor type
- University, hospital or other
- Collaborators
- NHS Fife
- Responsible party
- Sponsor
- Investigators
- Raymond Robson, Study director, NHS Fife LaboraoriesPAMELA MARKS, BSc Hons., Principal investigator, NHS Fife Area Laboratory
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01126905
- Sponsor's protocol ID
- 2010FAL1
- Status last verified
- Nov 2018
- First submitted
- 19 May 2010
- Last updated
- 30 Nov 2018
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 30 Nov 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Local Pilot Evaluation of Laboratory Monitoring of Renal Patients on Erythropoietin and /or Iron Therapy Using Mean Reticulated Haemoglobin Equivalent (RetHe) and Their Response to Therapy
- ClinicalTrials.gov ID
- NCT01126905
- Acronym / sponsor ID
- 2010FAL1
- Keywords
- Reticulated Haemoglobin Equivalent, Functional Iron Deficiency, Response to therapy, Iron deficiency
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 250 participants (actual)
- Lead sponsor
- University of UlsterUniversity, hospital or other
- Collaborators
- NHS Fife
- Study start
- Jun 2010
- Primary completion
- 7 Oct 2010 (actual)
- Study completion
- 7 Oct 2010 (actual)
- First posted
- 20 May 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Anaemia is a common complication of Chronic Kidney Disease (CKD) the management of which has been aided by the use of synthetic recombinant human erythropoietin therapy (r-HuEPO). This red cell stimulating agent creates the further complication of Functional Iron Deficiency (FID) where, despite normal iron stores, patients fail to respond to therapy as they do not possess enough available iron to meet the demand of increased red cell production. Effective response to r-HuEPO therapy depends on an appropriate monitoring of 'available' iron levels.
Previous research into the clinical utility of testing for reticulated haemoglobin concentrations (Ret He) instead of Serum Ferritin and Transferrin Saturation analysis has indicated an advantage as an iron deficient prognostic marker however, further knowledge is required on the use of this new laboratory test (RetHe) to predict Functional Iron Deficiency (FID) level and to study it's relationship with responses to therapy.
This proposed study aims to estimate a local working Normal (non deficient) and Iron Deficient Reticulated Haemoglobin Content (RET He) reference range from surplus anonamous samples. Routine monthly blood samples from Pre Dialysis and Haemodialysis patients will be used to evaluate the sensitivity and specificity of the RET He test compared to current laboratory tests and investigate its predictive ability for Functional Iron Deficiency in these patients.
Studying , measuring and statistically analysing the change in the RET He parameters in Haemodialysis and Pre Dialysis patients over 3 months will look for evidence of a direct relationship between RET He values and the patients response to therapy. The data will be used to provide a predictive picture of what levels of RET He indicate Functional Iron Deficiency.
The introduction of this test (RetHe) may provide clinicians with a one sample/one test control over iron therapies and ensure the patient gets the most benefit from erythropoietin therapy.
Detailed description
Reference Range Testing for new test RET-He will be performed on excess blood available on randomly selected anonamised samples obtained from the daily workload of the laboratory once all the clinically requested analysis has been completed.
100 samples (50 men / 50 women)determined to have normal parameters(as defined by Dacie et al, 10th Edition) and 100 samples (50 men / 50 women)determined to be iron deficient (as defined by Dacie et al, 10th Edition)will be processed for new test parameter (RetHe) under a coded number to ensure no identifying data is recorded. The samples will be archived and and held within the lab for 24 hours prior to routine disposal in accordance with NHS Fife Waste Management Policy.The data will be analysed using a paired t test to determine significant differences and reference range inferred inferred.
Evaluation of sensitivity / specificity of new Ret He test in determinimg iron deficiency and functional iron deficiency and it's response to terapy will be tested using Haemodialysis and Pre-Dialysis Patient Samples (~180 Haemodialysis Patients and ~250 Pre Dialysis Patients)that are obtained during their normal renal unit / clinic appointments.
All consenting NHS Fife Haemodialysis /Pre Dialysis patients will be allocated a 'Subject Identification Number' as part of this study (which will be noted at the top of their Consent Form). This number will be used by the Student Investigator to generate a confidential Coding Key which will be kept separate from data information and secure uner an NHS password protected computer. This will ensure care of personal information and will be used through-out the study by the student investigator to record all generated data.
Patients will be grouped into categories such as Dialysis / Pre Dialysis on a coded SPSS (statistical software) file.
All consenting patients will attend their routine scheduled Renal Clinic appointments as normal (no additional appointments are necessary for this pilot study)and their response to therapy will be observed using the new RetHe test parameter compared to existing laboratory tests utlised (FBC,Ferritin and Transferrin Saturation Levels)
Haemodialysis Patients - June 2010, July 2010*, August 2010
(* NB: In July 2010 Haemodialysis patients are scheduled to have their Ferritin and Transferrin Saturation Levels checked and therfore no additional sample will be required)
- Routine venesection of EDTA (purple topped) sample for Full Blood Count (FBC) Test
- Routine venesection of Clotted (yellow topped) sample for Biochemistry Analysis
- Additional venesection of extra yellow topped sample for non routine Ferritin Test(*usually scheduled every 3 months- routine date due: July 2010)
- Renal Unit Staff label samples and complete request form: Haematology section ticked for: FBC (as normal routine) , Retics (to allow addition of new Ret He test to FBC analysis) and Ferritin (additional request in June and August) Biochemistry section ticked for : All routinely requested Biochemistry tests (such as Urea and Electrolytes) plus additional request for Transferrin Saturation Levels (in June and August)
- Sample and Requests sent to Fife Area Lab for Analysis The project will be carried out within NHS Fife Area Laboratory Haematology Department and will involve the use of NHS premises, facilities and staff.
- Request checked at Laboratory Central Reception (sample and request form labelled with unique positive barcode identification)
- Request Forms sent to central request entry and samples delivered to appropriate laboratories
- FBC samples checked prior to analysis to check request details entered into Laboratory Host Computer System
- FBC sample loaded onto Sysmex XE2100 Haematology Analyser for testing
- Bidirectional Computer Link between Laboratory Host Computer System and Analyser ensures sample tested for FBC and additionally requested RETIC (reticulocyte analysis)
- Sysmex XE2100 automatically analyses sample for Red Blood Cell Indices and additionally uses fluorescent polymethine dye to stain for RNA/DNA content of reticulated cells (early red blood cell precursors). The analyser uses inbuilt Flow Cytometry and measures forward scatter to separate cells by size (this is reported as RBC-Y and RET-Y)
- Sysmex XE2100 RETIC Master software (recently upgraded packaged loaded onto NHS Fife Analysers)uses an algorithm (RET-He = 5.5569e 0.001RET-Y) to convert RET-Y into a reportable mean reticulocyte haemoglobin content (RET He) which is expressed in picograms.
- The sample once analysed is removed from the analyser and the results are either autovalidated and archived (if results are within normal range) or held for validation by a NHS Fife qualified Biomedical Scientist.
- The routinely requested FBC results are available for clinicians within same timescale as normal (no delay due to additional RetHe analysis)
- The sample is archived under their unique identifying barcode numbers and held within the lab for 24 hours prior to routine disposal in accordance with NHS Fife Waste Management Policy.
- The new RetHe value will be held on Sysmex XE2100 analyser (not activated as a reportable test to NHS Fife Biomedical Scientists or clinical staff.)
- The Student Investigator will (on same day as analysis) retrospectively generate a Renal Unit worklist from the Laboratory Host Computer System which will indicate: how many samples received, barcode numbers, names of patients.
- The Student Investigator will (on same day as analysis) retrospectively use the generated worklist to search the Sysmex XE2100 analysers for Ret-He test results and the host computer system for results of Ferritin and Transferrin Saturation Levels.
- The barcode number of the patient and their test results will initially be recorded in the student investigators laboratory handbook (the generated worklist will be discarded into NHS Fife Confidential Waste)
- The student investigator will record the test values into a coded SPSS (statistical software) file for appropriate analysis.
- The investigator will retrospectively match the test data with therapy regime data provided by the Renal Unit (monthly meetings)
Pre Dialysis Patients: June 2010, July 2010, August 2010
(NB: Pre Dialysis Patients are tested 3 monthly so over period of study should get a baseline sample from each consenting patient. Only those patients who are considered iron replete and are placed on 5 week course of iron therpay will be further tested at their follow-up appointments in order to measure response to therapy)
- Routine venesection of EDTA (purple topped) sample for Full Blood Count (FBC) Test, clotted (yellow topped) for Ferritin and clotted (yellow topped)sample for Transferrin Saturation Levels
- Renal Unit Staff label samples and complete request form: Haematology section ticked for: FBC (as normal routine) , Retics (to allow addition of new Ret He test to FBC analysis) and Ferritin (routine request) Biochemistry section ticked for : All routinely requested Biochemistry tests (such as Urea and Electrolytes) plus routine request for Transferrin Saturation Levels
- Sample and Requests sent to Fife Area Lab for Analysis
The project will be carried out within NHS Fife Area Laboratory Haematology Department and will involve the use of NHS premises, facilities and staff (same process as points 6 - 21 above)
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 16 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Renal Patients requested to participate in study (consent required)
Key inclusion criteria (2 listed)
- Two groups of random routine anonamised blood samples (for use in determinimg a local normal range for the Reticulated Haemoglobin Content [RetHe])will be included in the study:
- Normal red blood cell (RBC) Indices (Hb , Haematocrit, Mean Cell Volume ande Mean Cell Haemoglobin Content) ; an attempt will be made to select an equal mixture of men / women and an appropriate age spread to provide a valid control range for the group of test subjects (renal patients) The student Investigator will ask Haematology staff to record minimum details of iron deficient patients and "normal" test results noted at routine validation [positive identification number (barcode)/ age / sex] - these samples will be coded and additionally analysed for RetHe test.
Key exclusion criteria (2 listed)
- All renal patient who have had surgery and / or a Blood Transfusion OR bleeding episodes within the last month prior to the study are excluded as this would interfere with red cell parameters.
- All patients < 16 years and >85 years are excluded from the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Nov 2018.
Related trials for End-Stage Renal Failure
Active, not recruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
Not yet recruiting
Hypothermic Kidney Machine Perfusion With Omnisol
End Stage Renal Disease (ESRD), Kidney Transplant
Recruiting
Guiding Optimal Blood Pressure Management in Peritoneal Dialysis Pilot Trial
End Stage Kidney Disease (ESKD), Hypertension (HTN)
RecruitingObservational study
Physical Impairments in Children With Chronic Renal Failure
Chronic Kidney Failure, Chronic Kidney Diseases
RecruitingPhase 1
A Study to Test the Safety of the Study Drug Fosmanogepix and How the Body Handles It in Adults With Severe Kidney Failure on Dialysis
End Stage Renal Disease on Dialysis, Adult
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Raymond Robson study director
NHS Fife Laboraories
PAMELA MARKS, BSc Hons. principal investigator
NHS Fife Area Laboratory
Questions about this trial
What is this clinical trial studying?
An observational study of End-Stage Renal Failure and Functional Iron Deficiency, run by University of Ulster.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Nov 2018. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Nov 2018.